What Is Hormone Therapy Used For
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 12, 2021 Category: General Medicine Source Type: news

Sexual dysfunction hits some women harder than others as they age
(The North American Menopause Society (NAMS)) Sexual dysfunction often accompanies the menopause transition. Yet, not all women experience it the same. A new study identified the determinants that affect a woman's risk of sexual dysfunction and sought to determine the effectiveness of hormone therapy in decreasing that risk and modifying sexual behavior. Study results are published online in Menopause, the journal of The North American Menopause Society (NAMS). (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 6, 2021 Category: International Medicine & Public Health Source Type: news

With potential $4B Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

With potential $4B Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 28, 2020 Category: American Health Authors: Ron Leuty Source Type: news

With potential $4 billion Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

With potential $4 billion Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 28, 2020 Category: American Health Authors: Ron Leuty Source Type: news

New oral hormone drug for prostate cancer
The Food and Drug Administration has approved the use of a new oral hormone therapy drug, Relugolix, for treating advanced prostate cancer in men.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 22, 2020 Category: Endocrinology Source Type: news

FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer
MONDAY, Dec. 21, 2020 -- Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. Food and Drug Administration announced Friday. As opposed to currently... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer
Today, the FDA approved the first oral hormone therapy for treating advanced prostate cancer. This therapy may eliminate some patients ’ need to visit the clinic for treatments that require administration by a health care provider. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Transgender women retain athletic advantages after hormone therapy
Transgender women retain athletic advantages over cisgender women for 1-2 years after starting gender-affirming hormone therapy, according to a study published in theBritish Journal of Sports Medicine.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 17, 2020 Category: Endocrinology Source Type: news

Oral hormone therapy shown to significantly alter metabolome of menopausal women
(University of Massachusetts Amherst) Groundbreaking research led by a team of scientists including a University of Massachusetts Amherst biostatistician shows that oral hormone therapy (HT) significantly alters the metabolome of postmenopausal women. This finding, which examined blood specimens from the landmark Women's Health Initiative (WHI) study, may help explain the disease risks and protective effects associated with different regimens of hormone therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 16, 2020 Category: International Medicine & Public Health Source Type: news

Leaders in Health Care: Dr. Seema Shah, Planned Parenthood of Maryland
Shah says telehealth has made many services more accessible, including gender-affirming hormone therapy, sexually transmitted infection screenings and birth control prescriptions. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 4, 2020 Category: American Health Authors: Amanda Yeager Source Type: news

Menopause hormone therapy: Does it cause vaginal bleeding?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - December 2, 2020 Category: Consumer Health News Source Type: news

Transgender Americans use dangerous non-prescribed hormones
1 in 10 Transgender Americans may be using non-prescribed hormones that may cause serious health risks, as they aren’t insured or their insurance won’t cover costs of gender-affirming hormone therapy. CNN (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 25, 2020 Category: Endocrinology Source Type: news

10% of transgender Americans may be using non-prescribed hormones
1 in 10 transgender Americans may be using non-prescribed hormones that may cause serious health risks, as they aren’t insured or their insurance won’t cover costs of gender-affirming hormone therapy. CNN (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 25, 2020 Category: Endocrinology Source Type: news

Hormone Therapy for Prostate Cancer May Raise Heart Risks
Title: Hormone Therapy for Prostate Cancer May Raise Heart RisksCategory: Health NewsCreated: 11/20/2020 12:00:00 AMLast Editorial Review: 11/23/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 23, 2020 Category: Cancer & Oncology Source Type: news

Transgender Cancer Patients May Not Realize Treatment Can Interact With Their Hormone Therapy Transgender Cancer Patients May Not Realize Treatment Can Interact With Their Hormone Therapy
Transgender cancer patients often were not told of potential interactions between cancer treatment and gender-affirming hormone therapy, a case series reveals.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 20, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Hormone Therapy for Prostate Cancer May Raise Heart Risks
FRIDAY, Nov. 20, 2020 -- Hormone therapy can be a lifesaver for men with prostate cancer, but it also appears to put some at increased risk of heart problems, a new study reports. Long-term androgen deprivation therapy (ADT) increased the risk of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 20, 2020 Category: General Medicine Source Type: news

Prostate cancer: CRYM protein inhibits tumour growth
(Medical University of Vienna) Prostate cancer is caused by elevated hormone levels, and tumours are generally treated using hormone therapy. A research team headed by Lukas Kenner of MedUni Vienna in collaboration with David Heery from the University of Nottingham/UK and Sarka Pospisilova and Suzanne Turner of the University of Brno/Czech Republic have shown that the proteinμ-crystallin (CRYM) plays a significant part in tumour growth. The higher the levels of this protein that are present, the better the prognosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 18, 2020 Category: Cancer & Oncology Source Type: news

Female Hormone Rx Not Tied to Retinal Vascular Occlusion
TUESDAY, Nov. 17, 2020 -- Filling a prescription for female hormone therapy (FHT) is not associated with an increased risk for retinal artery occlusion (RAO) or retinal vein occlusion (RVO), according to a study published online Nov. 12 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 17, 2020 Category: Pharmaceuticals Source Type: news

Don't Miss Cardiovascular Risk Factors in Transgender Patients Don't Miss Cardiovascular Risk Factors in Transgender Patients
Cardiovascular disease risk is elevated among transgender individuals seeking gender-affirming hormone therapy, according to a retrospective study in 427 patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Breast Cancer and Hormone Therapy: What Do the New Data Mean? Breast Cancer and Hormone Therapy: What Do the New Data Mean?
A large British study takes another look at the question of the link between hormone replacement therapy and breast cancer.Medscape Ob/Gyn (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 13, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Transgender People Often Have Heart Risks: Study
THURSDAY, Nov. 12, 2020 -- Many transgender people who take hormone therapy have unaddressed risks for heart disease and stroke, a new study finds. These patients often have undiagnosed high blood pressure and high cholesterol, even in young... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 12, 2020 Category: General Medicine Source Type: news

AHA: CVD Risk Often Unaddressed for Transgender Population
TUESDAY, Nov. 10, 2020 -- Many transgender people receiving gender-affirming hormone therapy have cardiovascular disease risk factors, and a considerable proportion are not receiving appropriate therapies, according to a study presented at the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 10, 2020 Category: Pharmaceuticals Source Type: news

Under-insured transgender americans turn to riskier sources for gender-affirming hormones
(American Academy of Family Physicians) Transgender people who lack access to insurance coverage for gender-affirming hormone therapy are more likely to use hormones from sources other than a licensed prescriber, compared to those with insurance coverage. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 10, 2020 Category: International Medicine & Public Health Source Type: news

Transgender patients may have increased risk of cardiovascular diseases
According to a study presented at the American Heart Association Scientific Sessions 2020, transgender patients undergoing gender-affirming hormone therapy may have an increased risk of cardiovascular diseases.The Cardiology Advisor (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 9, 2020 Category: Endocrinology Source Type: news

Breast cancer recurs after treatment because hormone therapy only puts some cells to "sleep," suggests study
(Natural News) Scientists have long debated whether the hormone therapy that is used to treat breast cancer actually kills all of the breast cancer cells completely or simply puts them into a dormant “sleeper” state. However, a new study has found that both camps could be right and that these drugs kill some cells while... (Source: NaturalNews.com)
Source: NaturalNews.com - November 4, 2020 Category: Consumer Health News Source Type: news

Breast Cancer Surgery Feasible for Most Fit Older Women
Hormone therapy alone may be as good as surgery if life expectancy is less than four years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 23, 2020 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Surgery, Geriatrics, Conference News, Source Type: news

Advanced prostate cancer has an unexpected weakness that can be targeted by drugs
(Kanazawa University) Kanazawa University researchers reported that the SUCLA2 gene is frequently involved in the deletion of the tumor suppressor gene RB1 in advanced prostate cancer. RB1 deletion makes cells resistant to hormone therapy but SUCLA2 deletion induces a metabolic weakness. The study showed that thymoquinone selectively killed SUCLA2-deficient prostate cancer cellsinvitro andinvivo. The findings highlight a vulnerability of advanced prostate cancer cells that can be targeted by drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 7, 2020 Category: Cancer & Oncology Source Type: news

Scientists discover potential new treatment for breast cancer
A team of Irish scientists may have discovered a potential new treatment option for patients with breast cancer who are resistant to hormone therapy, according to a study published in the journalCancer Research.Independent.ie (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 5, 2020 Category: Endocrinology Source Type: news

Judgment Free Online Platform Key to Helping Suicidal People, Says Survivor
A suicide survivor shares her story of how an online community helped her overcome anxiety and depression. Credit: Unsplash / Dan M By Fairuz AhmedNEW YORK, Sep 28 2020 (IPS) Romana Hoque had it all, a comfortable life, a happy family. Despite this, the 43-year-old second-generation immigrant from Indonesia living in the United States was depressed enough to contemplate suicide. Hoque, in an exclusive interview with Inter Press Service (IPS), said despite her comfortable life, not being able to conceive resulted in her feeling so depressed that she tried to take her own life. She shared her story during September – ...
Source: IPS Inter Press Service - Health - September 28, 2020 Category: International Medicine & Public Health Authors: Fairuz Ahmed Tags: Aid Featured Gender Global Headlines Health TerraViva United Nations Fuzia 2020 Source Type: news

New hormone therapies for hot flashes offer enhanced benefits and minimized risk
(The North American Menopause Society (NAMS)) Hormone therapy remains the best proven method for managing menopause symptoms such as hot flashes. Research continues, however, in the area to identify novel approaches to estrogen therapy that minimize any associated risks. Dr. Hugh Taylor from Yale School of Medicine will discuss some of the latest developments, including fetal estrogens, during the 2020 Pre-Meeting Symposium of The North American Menopause Society (NAMS). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 28, 2020 Category: Cancer & Oncology Source Type: news

How hormone therapy slows progression of atherosclerosis
(The North American Menopause Society (NAMS)) As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis. A study based on Early Versus Late Intervention Trial With Estradiol (ELITE) data evaluated the underlying mechanism of such benefit and will be presented during the 2020 Virtual Annual Meeting of The North American Menopause Society (NAMS), opening on September 28. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 28, 2020 Category: International Medicine & Public Health Source Type: news

First new drug in years reduces recurrence in high risk HR+ early breast cancer
(European Society for Medical Oncology) Lugano, Switzerland, 20 September 2020 - Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 20, 2020 Category: International Medicine & Public Health Source Type: news

PARPi olaparib for the targeted treatment of metastatic prostate cancer
(Vall d'Hebron Institute of Oncology) Results from the PROfound phase III study open up a new treatment avenue for the more precise and effective treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed with hormonal therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 20, 2020 Category: International Medicine & Public Health Source Type: news

Factors Tied to Hormone Therapy Use After Oophorectomy ID'd
MONDAY, Aug. 17, 2020 -- Age at surgery, education level, and preventive mastectomy are associated with hormone therapy (HT) use after preventive oophorectomy in BRCA mutation carriers, according to a study published online Aug. 10 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 17, 2020 Category: Pharmaceuticals Source Type: news

Delaying prostate cancer radiation therapy offers room for flexibility in pandemic peak
(Brigham and Women's Hospital) A new study by investigators from Brigham and Women's Hospital found that for men with unfavorable intermediate-risk or high-risk localized prostate cancer, who are receiving radiation and hormone therapy, delaying radiation while remaining on hormone therapy is unlikely to impact survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 13, 2020 Category: Cancer & Oncology Source Type: news

Age, education, and surgical history affect hormone use after oophorectomy
(The North American Menopause Society (NAMS)) CLEVELAND, Ohio (August 12, 2020)--Removal of the ovaries before natural menopause (surgical menopause) often exacerbates menopause symptoms and places women at increased risk for heart disease, osteoporosis, and cognitive decline. A new study identified the frequency of hormone therapy (HT) use and factors that determine who is more likely to use hormones after oophorectomy to manage symptoms. Study results are published online today in Menopause, the journal of The North American Menopause Society (NAMS). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 12, 2020 Category: Cancer & Oncology Source Type: news

Testicular Seminoma During Transgender Woman Hormone Therapy Testicular Seminoma During Transgender Woman Hormone Therapy
Gender-affirming hormone therapy unmasked an unsuspected hCG-secreting testicular seminoma in a transgender woman. How was this case diagnosed?Journal of the Endocrine Society (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 4, 2020 Category: Radiology Tags: Diabetes & Endocrinology Journal Article Source Type: news

Studies suggest a fasting diet could boost breast cancer therapy
(University of Southern California) A USC-led team of scientists has found that a fasting-mimicking diet combined with hormone therapy has the potential to help treat breast cancer, according to newly published animal studies and small clinical trials in humans. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 21, 2020 Category: International Medicine & Public Health Source Type: news

Women taking menopausal hormone therapy may be more resistant to urine infections
(European Association of Urology) In the first analysis of its kind, US-based doctors have shown that women who take menopausal hormone therapy (MHT, also known as HRT) have a greater variety of beneficial bacteria in their urine, possibly creating conditions that discourage urinary infections. The study also shows that women who suffer from recurrent urine infections have fewer different types of bacteria in urine than women who don't have infections, making them more prone to infections. Presented at the European Association of Urology Virtual Congress (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 17, 2020 Category: International Medicine & Public Health Source Type: news

Prescribers Should Restrict the Use of Non-FDA-Approved Compounded Bioidentical Hormones, Except for Specific Medical Circumstances
The use of compounded bioidentical hormone therapies (cBHTs) — an increasingly popular approach to relieve symptoms of menopause and male hypogonadism — should be limited to the small number of patients who cannot benefit from an FDA-approved hormone therapy product, says a new report from the National Academies of Sciences, Engineering, and Medicine. (Source: News from the National Academies)
Source: News from the National Academies - July 1, 2020 Category: Science Source Type: news

Underlying Breast Cancer Risk and Menopausal Hormone Therapy Underlying Breast Cancer Risk and Menopausal Hormone Therapy
In what ways might the use of hormonal therapy impact the underlying risk of breast cancer among postmenopausal women?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 26, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Contraceptives Beneficial for Premature Ovarian Insufficiency
THURSDAY, June 25, 2020 -- For women with premature ovarian insufficiency (POI), continuous use of combined oral contraceptives (COC) is associated with increased bone mineral density (BMD), similar to that seen with high-dose hormone therapy (HT),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 25, 2020 Category: Pharmaceuticals Source Type: news

AHA News: Hormone Therapy No Cure-All For'Low T' In Aging Men
Title: AHA News: Hormone Therapy No Cure-All For'Low T'In Aging MenCategory: Health NewsCreated: 6/17/2020 12:00:00 AMLast Editorial Review: 6/18/2020 12:00:00 AM (Source: MedicineNet Mens Health General)
Source: MedicineNet Mens Health General - June 18, 2020 Category: Primary Care Source Type: news

AHA News: Hormone Therapy No Cure-All For'Low T' In Aging Men
WEDNESDAY, June 17, 2020 (American Heart Association News) -- Testosterone therapy ads promise to help aging men recapture their vitality, decrease body fat and enhance libido. But hormone treatments – while medically necessary for some men –... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 17, 2020 Category: General Medicine Source Type: news

Cross-sex hormone therapy may affect metabolic profile
Gender-affirming hormone therapy may negatively affect lipid metabolism and glucose levels in transgender men, according to research published in the Journal of the Endocrine Society.Endocrinology Advisor (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 11, 2020 Category: Endocrinology Source Type: news

Does Hormone Therapy Protect the Heart? Does Hormone Therapy Protect the Heart?
The question of whether hormonal therapy provides cardiovascular benefit to women is a controversial one.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Prostate Cancer Drug Could Be 'Game Changing'
For men with advanced prostate cancer, a new hormone therapy pill works better than standard injections -- and carries a much lower risk of heart attack or stroke. (Source: WebMD Health)
Source: WebMD Health - May 29, 2020 Category: Consumer Health News Source Type: news

Hormone Therapy and Sarcopenia in Postmenopausal Women Hormone Therapy and Sarcopenia in Postmenopausal Women
Might hormone replacement therapy attenuate the loss of muscle mass and strength that often occurs in postmenopausal women?Menopause (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 29, 2020 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news